140 related articles for article (PubMed ID: 31753713)
1. In vitro basophil activation is reduced by short-term omalizumab treatment in hydrolyzed wheat protein allergy.
Chinuki Y; Yagami A; Adachi A; Matsunaga K; Ugajin T; Yokozeki H; Hayashi M; Katayama I; Kohno K; Shiwaku K; Morita E
Allergol Int; 2020 Apr; 69(2):284-286. PubMed ID: 31753713
[No Abstract] [Full Text] [Related]
2. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
Voskamp AL; Gillman A; Symons K; Sandrini A; Rolland JM; O'Hehir RE; Douglass JA
J Allergy Clin Immunol Pract; 2015; 3(2):192-9. PubMed ID: 25640470
[TBL] [Abstract][Full Text] [Related]
4. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
Gomez G
Front Immunol; 2019; 10():175. PubMed ID: 30792720
[TBL] [Abstract][Full Text] [Related]
5. Antigen-induced expression of CD203c on basophils predicts IgE-mediated wheat allergy.
Tokuda R; Nagao M; Hiraguchi Y; Hosoki K; Matsuda T; Kouno K; Morita E; Fujisawa T
Allergol Int; 2009 Jun; 58(2):193-9. PubMed ID: 19240377
[TBL] [Abstract][Full Text] [Related]
6. The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders.
Stitt JM; Dzieciatkowska M; Edwards MG; Hansen K; Hedlund G; Dreskin SC
Clin Exp Allergy; 2018 Jul; 48(7):898-901. PubMed ID: 29671921
[No Abstract] [Full Text] [Related]
7. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
9. Characterization of causative allergens for wheat-dependent exercise-induced anaphylaxis sensitized with hydrolyzed wheat proteins in facial soap.
Yokooji T; Kurihara S; Murakami T; Chinuki Y; Takahashi H; Morita E; Harada S; Ishii K; Hiragun M; Hide M; Matsuo H
Allergol Int; 2013 Dec; 62(4):435-45. PubMed ID: 23963475
[TBL] [Abstract][Full Text] [Related]
10. Wheat allergy in celiac children.
Martín-Muñoz MF; Rivero D; Díaz Perales A; Polanco I; Quirce S
Pediatr Allergy Immunol; 2016 Feb; 27(1):102-5. PubMed ID: 26360318
[No Abstract] [Full Text] [Related]
11. Immunoglobulin-E-binding epitopes of wheat allergens in patients with food allergy to wheat and in mice experimentally sensitized to wheat proteins.
Denery-Papini S; Bodinier M; Pineau F; Triballeau S; Tranquet O; Adel-Patient K; Moneret-Vautrin DA; Bakan B; Marion D; Mothes T; Mameri H; Kasarda D
Clin Exp Allergy; 2011 Oct; 41(10):1478-92. PubMed ID: 21771117
[TBL] [Abstract][Full Text] [Related]
12. Allergy to deamidated gluten in patients tolerant to wheat: specific epitopes linked to deamidation.
Denery-Papini S; Bodinier M; Larré C; Brossard C; Pineau F; Triballeau S; Pietri M; Battais F; Mothes T; Paty E; Moneret-Vautrin DA
Allergy; 2012 Aug; 67(8):1023-32. PubMed ID: 22737987
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of omalizumab in adult patients with wheat-dependent exercise-induced anaphylaxis: Reduction of in vitro basophil activation and allergic reaction to wheat.
Chinuki Y; Kohno K; Hide M; Hanaoka K; Okabe T; Fukunaga A; Oda Y; Adachi A; Ugajin T; Yokozeki H; Suzuki R; Sugiyama A; Kishikawa R; Yamasaki O; Morita E
Allergol Int; 2023 Jul; 72(3):444-450. PubMed ID: 36641300
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
15. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
16. Increase in human basophils IgE-mediated stimulation by omalizumab: a role for membrane FcγRs?
Chirumbolo S; Olivieri M
J Allergy Clin Immunol; 2014 May; 133(5):1493-4. PubMed ID: 24642141
[No Abstract] [Full Text] [Related]
17. Polyphenol Interactions Mitigate the Immunogenicity and Allergenicity of Gliadins.
Pérot M; Lupi R; Guyot S; Delayre-Orthez C; Gadonna-Widehem P; Thébaudin JY; Bodinier M; Larré C
J Agric Food Chem; 2017 Aug; 65(31):6442-6451. PubMed ID: 28190352
[TBL] [Abstract][Full Text] [Related]
18. [Immunobiology of wheat allergen and allergic disease].
Takahashi H; Morita E
Arerugi; 2008 Nov; 57(11):1094-101. PubMed ID: 19052503
[No Abstract] [Full Text] [Related]
19. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular responses to gliadin in wheat-dependent, exercise-induced anaphylaxis.
Lehto M; Palosuo K; Varjonen E; Majuri ML; Andersson U; Reunala T; Alenius H
Clin Exp Allergy; 2003 Jan; 33(1):90-5. PubMed ID: 12534555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
